July 2024 - Defence Therapeutics

Defence Therapeutics Granted Cnri-H From The Canadian Nuclear Laboratories To Accelerate The Development Of Its Radio-Immuno-Conjugates Program

by FiveSenses | Jul 24, 2024 | News Release

Vancouver, BC, Canada, July 24th, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to...

Defence Receives No Objection Letter From Health Canada For Phase I Trial Of Its Accum-002 (Accutox) As An Anti-Cancer Molecule In Patients With Melanoma

by FiveSenses | Jul 8, 2024 | News Release

Vancouver, BC, Canada, July 8th, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to...

Defence Therapeutics Granted Cnri-H From The Canadian Nuclear Laboratories To Accelerate The Development Of Its Radio-Immuno-Conjugates Program

Defence Receives No Objection Letter From Health Canada For Phase I Trial Of Its Accum-002 (Accutox) As An Anti-Cancer Molecule In Patients With Melanoma

Recent Posts

Recent Comments

Archives

Categories

Meta

Connect with us:
Sign up for news and investor alerts.